Invitae Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Invitae şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-3,542.9%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-3,542.9%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Dec 20

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Aug 09

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: NVTA.Q şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: NVTA.Q şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Invitae Piyasaya Karşı Temettü Getirisi

NVTA.Q temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (NVTA.Q)	n/a
Pazarın Alt %25'i (US)	1.3%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Healthcare)	1.6%
Analist tahmini (NVTA.Q) (3 yıla kadar)	0%

Önemli Temettü: NVTA.Q şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, NVTA.Q şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: NVTA.Q şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: NVTA.Q herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Invitae Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

Invitae Launches Unlock Behind the Seizure Program for Pediatric Epilepsy Patients

First Amended Disclosure Statement Approved for Invitae Corporation

Laboratory Corporation of America Holdings (NYSE:LH) agreed to acquire Substantially all Assets of Invitae Corporation for approximately $240 million.

Invitae Unveils New Research for Breast Cancer Patients with Variants of Uncertain Significance

Invitae Launches Update to Invitae Generation: Clinical Variant Modeling Improves Variant Classification

Invitae Corporation Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023

Motion for Asset Sale Filed by Invitae Corporation

Invitae Corporation Filed for Bankruptcy

Invitae Corporation(OTCPK:NVTA) dropped from S&P TMI Index

The New York Stock Exchange to Commence Delisting Proceedings against Invitae

Invitae Corporation May File for Bankruptcy

New minor risk - Market cap size

Cautious Investors Not Rewarding Invitae Corporation's (NYSE:NVTA) Performance Completely

Invitae Corporation Announces Board Changes

Invitae Corporation Announces the Retirement of Robert L. Nussbaum as Chief Medical Officer, Effective December 29, 2023

Price target decreased by 11% to US$1.31

Invitae Corporation Appoints Ana J. Schrank as Chief Accounting Officer

Consensus EPS estimates fall by 119%

New major risk - Financial position

Invitae Corporation Reaffirms Earnings Guidance for the Full Year 2023

Price target increased by 30% to US$1.92

Third quarter 2023 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q3, 2023 Results on Nov 08, 2023

Invitae Corporation Announces Findings from the Study to Date on Uncertain Results from Hereditary Disease Genetic Testing

Invitae Corporation Appoints David Sholehvar as Chief Operating Officer, Effective November 13, 2023

Price target decreased by 14% to US$1.58

Invitae Announces Results of Its Collaborative Study on Universal Hereditary Cancer Genetic Testing in All Patients with Breast Cancer in A Rural Population in the Annals of Surgical Oncology

Invitae Corporation Announces Change of Chief Financial Officer, Effective October 2, 2023

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

Invitae Receives Notice of Non-Compliance with NYSE Minimum Share Price Continued Listing Standard

New major risk - Financial position

Invitae Corporation Announces Clinical Trial Results Support Genetic Testing of All Patients with Prostate Cancer

Price target decreased by 13% to US$1.70

Consensus EPS estimates fall by 34%

Invitae Corporation Provides Revenue Guidance for the Year 2023

Invitae Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 8.2% to US$1.87

Second quarter 2023 earnings: EPS misses analyst expectations

Invitae: Revenue Troubles Build

Invitae Corporation to Report Q2, 2023 Results on Aug 08, 2023

Invitae Is Treading In Competitive Waters

Invitae Corporation Announces Executive Changes

Invitae Corporation's (NYSE:NVTA) Prospects Need A Boost To Lift Shares

Invitae Corporation Announces Nine Studies to Be Presented At the 2023 American Society of Clinical Oncology Annual Meeting Reinforce the Critical Role of Germline Genetic Testing in Oncology

Invitae Announces CFO Changes

President recently sold US$54k worth of stock

Invitae Corporation Announces It Intends to Appeal the Verdict Delivered by A Jury At the United States District Court

Consensus EPS estimates fall by 19%

First quarter 2023 earnings: EPS misses analyst expectations

Price target decreased by 10.0% to US$2.26

Full year 2022 earnings: EPS misses analyst expectations

Invitae Corporation to Report Q4, 2022 Results on Feb 28, 2023

Price target decreased by 7.4% to US$2.51

Invitae Corporation Appoints William H. Osborne to its Board of Directors

Invitae: What Happened At The JP Morgan Health Conference

Invitae guides Q4 revenue above estimates

Director recently sold US$115k worth of stock

Invitae Likely Hasn't Reached The Bottom Yet

Invitae Releases Data Use Transparency Report, Demonstrating the Impact of Patient Data on Genetic Research

Invitae Launches Rare Patient Network for Pediatric Patients with Rare Neurodevelopmental Diseases

Consensus forecasts updated

Invitae: This Turnaround Could Be Painful

Invitae Corporation Reiterates Earnings Guidance for the Year 2022

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Invitae Corporation Reports Asset Impairments for the Third Quarter Ended September 30, 2022

Invitae GAAP EPS of -$1.27 misses by $0.43, revenue of $133.54M beats by $2.16M

Invitae Corporation Study Shows Therapy Informed by Genetic Testing Reduces Seizures in Some Patients with Epilepsy

Invitae Corporation to Report Q3, 2022 Results on Nov 08, 2022

Price target decreased to US$2.71

Invitae Stock: Losses And Debt Suggest Bearish Sentiment Is Deserved

Why Invitae Corporation Could Underperform

Invitae Corporation Reiterates Revenue Guidance for the Year 2022

Invitae maintains 2022 financial guidance as Q2 results beat on top and bottom lines

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi